Glycoprotein Acetylation
GLYCA
Description
"Glycoprotein Acetylation" (GlycA) test detects markers of systemic inflammation that may contribute to chronic diseases such as cardiovascular conditions, diabetes, or autoimmune disorders. It’s often used when symptoms like joint pain, fatigue, or metabolic concerns are present and further evaluation is needed. Elevated GlycA levels indicate persistent inflammatory activity. The results help shape personalized care plans, including lifestyle changes, anti-inflammatory support, or additional diagnostics. Monitoring GlycA over time supports inflammation tracking and strengthens long-term health management.
Category
Glycoproteins, Proteins
Procedure
Invasive
Sample Type
Blood – Serum
Units
Micromoles Per Liter
Procedure Category
Blood Draw
Test Group
Basic Cardiovascular Group, Complete Cardiovascular Group, Basic Inflammation Group, Complete Inflammation Group
Test Group Description
Basic Cardiovascular Group: This group includes fundamental tests targeting essential markers related to cardiovascular health, providing foundational insights into cholesterol levels, blood pressure, and other key factors. Basic Inflammation Group: This set of tests helps evaluate the body's inflammatory response, providing valuable information for diagnosing and managing inflammatory conditions. Complete Cardiovascular Group: This group contains comprehensive tests for an extensive evaluation of cardiovascular health, providing thorough insights into heart-related conditions beyond basic assessments. Complete Inflammation Group: Extensive tests offer a comprehensive assessment of inflammatory markers, yielding detailed insights into inflammation levels and related health conditions.
Optimal Range
For All Individuals:
Conventional Unit: 100–300 µmol/L
SI Unit: 100–300 µmol/L
Normal Range
For Men:
Conventional Unit: 273–487 µmol/L
SI Unit: 273–487 µmol/L
For Women:
Conventional Unit: 299–522 µmol/L
SI Unit: 299–522 µmol/L
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Hypertension (High blood pressure)
Hypercholesterolemia (High levels of cholesterol in the blood)
Inflammation
Obesity
Smoking
Type 2 diabetes (Metabolic disorder characterized by high blood sugar levels)
Key Reasons For Testing
Regulation of Protein Function: Modulates protein activity in cellular processes such as signaling, metabolism, and gene expression.
Cellular Signaling Pathways: Influences pathways related to cell growth, differentiation, and survival.
Epigenetic Modification: Contributes to chromatin structure and gene expression changes, impacting cellular function.
Disease Mechanisms: Linked to conditions like cancer, ...
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Bell JD, Brown JC, Nicholson JK, Sadler PJ. Assignment of resonances for “acute-phase” glycoproteins in high-resolution proton NMR spectra of human blood plasma. FEBS Lett. 1987;215(2):311-315.
[2] McGill MR, Li F, Sharpe MR, et al. Serum glycoprotein acetylation is a novel biomarker of hepatic mitochondrial dysfunction in non-alcoholic fatty liver disease. Hepatology. 2015;61(4):1178-1187.
[3] Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of proton nuclear magnetic resonance spectroscopic and mathematical techniques for lipoprotein subclass profiling with applications to cardiovascular disease. Clin Chem.1992;38(9):1632-1638.
[4] Kujala UM, Makinen VP, Heinonen I, et al. Long-term leisure-time physical activity and serum metabolome. Circulation. 2013;127(3):340-348.
[5] Fischer K, Kettunen J, Würtz P, et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med. 2014;11(2):e1001606.
[6] Würtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation. 2015;131(9):774-785.
[7] Dullaart RPF, Gruppen EG, Connelly MA, et al. GlycA, a novel pro-inflammatory glycoprotein biomarker, and incident cardiovascular disease: relationship with C-reactive protein and renal function. Atherosclerosis. 2016;252:123-130.
[8] Barrios C, Spector TD, Menni C. Glycoprotein acetyls (GlycA) as a novel inflammatory marker in chronic disease. Clin Chem Lab Med. 2016;54(2):257-263.
[9] Connelly MA, Gruppen EG, Wolak-Dinsmore J, et al. GlycA, a novel biomarker of systemic inflammation, is associated with disease severity in chronic inflammatory arthritis. Arthritis Res Ther. 2016;18:86.
[10] Ritchie SC, Würtz P, Nath AP, et al. The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection. Cell Syst. 2015;1(4):293-301.
[11] Magnoni M, Colleoni A, Camozzi M, et al. Endothelial function in patients with a history of preeclampsia: a unique inflammation-related vascular mechanism in hypertension. Am J Obstet Gynecol. 2017;217(6):692.e1-692.e7.
[12] Akinkuolie AO, Glynn RJ, Ridker PM, Libby P, Zachariah JP. Novel protein glycan side-chain biomarkers and risk of cardiovascular disease. J Am Heart Assoc. 2020;9(11):e015192.
[13] Gruppen EG, Dullaart RPF, Connelly MA. GlycA: a new biomarker for systemic inflammation. Clin Chim Acta.2019;498:67-73.
[14] Yao X, Li W, Du W, et al. Glycoprotein acetylation (GlycA) in patients with rheumatoid arthritis: associations with disease activity and coronary artery disease risk. J Rheumatol. 2021;48(5):658-664.